Subconjunctival bevacizumab injection in treatment of pterygium

This study determined the clinical effect of subconjunctival administration of bevacizumab in patients with primary and recurrent pterygium. The study was an off-label, single-dosing, interventional case series involving 22 patients with primary and recurrent pterygium. They received subconjunctival bevacizumab [0.2cc]. Pterygium vascularity and thickness was graded. The size of the pterygium [measured by surface area in cm[2]] was recorded from baseline to 12 weeks, after injection. Treatment-related complications and adverse events were reported. The main outcome of measurements was the change in size, vascularity, thickness, color intensity. There were 15 males [68.2%] and 7 females [31.8%] of 22 patients with a mean age of 45.5 years [SD 11.68 years]. One cases didn't cooperate, and excluded. There was a significant difference in the mean surface area of pterygium at different intervals [P < 0.05] and the size of pterygium was reduced. On comparison of the mean pterygium size, there was no significant difference between men and women [P >0.05]. There was a significant reduction in the mean pterygium size of patients younger than 45 years in comparison to those older than 45 years after three month [P =0.037], but after 6 months, this difference was not significant [P = 0.338]. Average changes in pterygium size for both eyes were not different. The reduction of color intensity in both eyes was significant [P =0.031]. Subconjuctival bevacizumab injection is useful in management of patients with primary and recurrent pterygium without significant local or systemic adverse effects